The unlicensed medicines playbook: how GCC hospitals legally access drugs before ministry approval.

Every GCC hospital pharmacist has had the same conversation. A consultant signs a prescription for a medicine the local pharmacy can't dispense. Procurement tells them the molecule isn't registered. The pharmacist emails around and finds out, eventually, that it can be imported — but nobody on the desk has ever done it. The patient is on a ward. The clock is running.

This is the post we wish someone had put on the internet five years ago. It is a practical playbook for the three legal routes that every GCC health authority operates for unlicensed or unregistered medicines, written in the order a working hospital pharmacist actually hits the questions.

What “unlicensed” actually means (and what it doesn't)

In the GCC, an unlicensed medicine is any pharmaceutical that does not currently hold a Marketing Authorisation in the destination country. That covers three separate situations, and conflating them is where most procurement conversations go wrong on day one:

1. Never registered locally. The molecule or brand has never been submitted to the national authority. Common for orphan drugs, rare-disease therapies, niche oncology lines, and recently approved US/EU innovations.
2. Registered elsewhere, not here. The product has an EMA or FDA authorisation, and possibly a Saudi or UAE file in progress, but no current local licence. Common when a hospital is used to sourcing from a European formulary.
3. De-listed or temporarily withdrawn. The product was registered locally but the manufacturer let the registration lapse or paused supply. Common for older essential medicines where the commercial case for renewal is weak.

None of these mean “illegal.” All three are addressable through the regulated pathways below. They just require different cover letters.

The three legal pathways every GCC authority runs

Every GCC health authority operates some version of the same three-route framework — the names and acronyms change, the logic does not:

1. Named-patient import (the default)

A treating physician identifies a specific patient, by name or unique hospital identifier, and issues a prescription for a medicine not currently registered locally. The hospital pharmacy, or a licensed importer acting on its instructions, applies for an import permit on a per-patient, per-quantity basis. The permit is bounded to the treatment course.

This is the workhorse. It is the pathway most hospital pharmacists will use for the majority of unlicensed requests, and the one that every supplier worth the name has a documented process for.

2. Compassionate use / early access

Used for medicines still in clinical development, or recently approved abroad but not yet commercially launched. The patient has a serious or life-threatening condition with no satisfactory authorised alternative. The manufacturer supplies the product through a formal compassionate-use programme, with the destination authority's permission, usually free of charge or at cost.

Slower and more paperwork-heavy than named-patient import, because it requires the manufacturer's participation. But for the right case, it is the only route.

3. Special-access / specific-import authorisation (hospital-level)

Some authorities — SFDA in Saudi Arabia in particular — operate a hospital-level special-access register that allows designated tertiary hospitals to hold a rolling permission for a defined list of unlicensed specials, rather than apply per patient every time. The product list is reviewed periodically.

This route is where the big oncology centres and the military medical services sit. It is not a route most general hospitals will qualify for, but it is worth knowing it exists — because when you meet a hospital that runs on it, the conversation changes.

Country-by-country: how each GCC authority actually runs it

United Arab Emirates — MOHAP (federal) & DHA (Dubai) & DoH (Abu Dhabi)

The UAE runs a federated system: MOHAP issues the federal import permit, but within Dubai and Abu Dhabi the Dubai Health Authority and Abu Dhabi Department of Health add an emirate-level pharmacy licence layer on top. For a named-patient import into a Dubai hospital, you will touch all three in the paper trail.

Practical timing: 7–14 working days from complete file to cleared customs for a non-cold-chain line. Oncology and biologicals run longer. The permit is patient-specific and quantity-bounded — a three-month course is routine, a twelve-month supply requires justification.

Saudi Arabia — SFDA

The Saudi Food and Drug Authority runs the most mature unlicensed-medicines apparatus in the GCC. Every named-patient import goes through SFDA's e-permit portal, and hospitals that handle volume operate a standing relationship with a licensed local pharmaceutical establishment to process applications.

The SFDA special-access register is the route that MoD hospitals, KFSH and the Saudi-German chain use for recurring unlicensed lines. For a one-off named-patient request, realistic timing is 10–20 working days end to end.

Qatar — MoPH

The Ministry of Public Health runs a named-patient pathway through the Department of Pharmacy and Drug Control. Hamad Medical Corporation is the dominant user of the route, and its pharmacy has a streamlined internal workflow that external hospitals can follow. 7–14 working days for standard lines, assuming a complete file.

Kuwait — MoH

The Ministry of Health operates the Kuwait Drug & Food Control route, with named-patient imports going through the Registration Department. Turnarounds are variable — a clean file can clear in 10 working days; anything with queries can sit for three weeks.

Oman, Bahrain — MoH

Smaller volumes, less formal infrastructure, but the pathway exists. Oman's MoH and Bahrain's NHRA both operate named-patient imports on a case-by-case letter basis. Work with a supplier that has a Gulf-wide regulatory footprint rather than a single-country specialist.

The documentation pack that actually clears

The single biggest cause of delays on unlicensed imports is incomplete paperwork, not regulatory refusal. A proper named-patient file for any GCC authority should include:

• Physician prescription — on hospital letterhead, signed, identifying the named patient (or unique ID), diagnosis (ICD-10), dosing regimen, and duration of treatment.
• Hospital pharmacy import letter — confirming clinical justification, unavailability of a registered alternative, and the pharmacy's undertaking to dispense under controlled conditions.
• Manufacturer's Certificate of Analysis (CoA) — for the specific batch being supplied. Not a generic product CoA.
• WHO-GMP certificate — or EU-GMP / US-FDA equivalent, for the manufacturing site.
• Certificate of Pharmaceutical Product (CoPP) — WHO-format, issued by the exporting country's authority.
• Certificate of Origin — from an accredited chamber of commerce in the exporting country.
• Destination-market pack insert — original artwork, with Arabic translation where the authority requires it.
• Cold-chain documentation — for 2–8°C or −20°C lines, the validated packaging, shipper configuration, and logger data.
• Invoice and packing list — matched to the import permit quantity down to the last vial.

The pack is boring. The pack also decides whether the container sits at the airport for ten days or clears in two.

Realistic timelines

If you are scoping a named-patient import and need to tell a consultant what to expect, these are honest figures based on Gulf-wide hospital work over the last three years:

• Standard solid-dose oral line, complete file, UAE or Qatar: 7–10 working days.
• Oncology or biological, cold-chain, UAE or KSA: 14–21 working days.
• Orphan drug, manufacturer-direct compassionate-use: 4–8 weeks.
• Special-access register addition (SFDA hospital): variable — typically 6–10 weeks for a new molecule.

Four mistakes that cost you a week

1. Generic CoA, not batch-specific. Every GCC authority will bounce the file. Insist on a batch-matched CoA from the supplier before the permit application goes in.
2. Prescription without ICD-10. A clinical letter that says “for compassionate use” but doesn't state the diagnosis code will sit on a reviewer's desk.
3. Pack insert in English only for an Arabic-required authority. Translate before the shipment lands, not after.
4. Cold-chain shipper without validated logger data. No logger, no release. Every logger reading is part of the file.

FAQ

Is importing unlicensed medicines legal in the GCC?

Yes, under regulated pathways run by each national authority — named-patient import, compassionate use, and special-access programmes. The routes differ in detail across MOHAP, SFDA, DHA, MoPH and MoH Kuwait, but the underlying legal basis is the same: hospitals can access unlicensed medicines where there is a documented clinical need and the authority has issued a permit.

What's the difference between named-patient and compassionate use?

Named-patient import is physician-initiated, patient-specific, and quantity-bounded to a treatment course. Compassionate use is manufacturer-run, for products still in clinical development or pre-commercial launch, and requires the manufacturer's active participation and authority sign-off.

How fast can a hospital clear a named-patient request?

A complete documentation pack, a clean cold-chain file, and a GCC-experienced supplier can clear a standard named-patient import in 7–14 working days. Oncology and biological lines sit at the longer end.

Does M Care handle named-patient and compassionate-use imports?

Yes. We run named-patient and compassionate-use shipments into UAE, Saudi Arabia, Kuwait, Qatar, Oman and Bahrain, with a Mumbai-based regulatory desk that handles the documentation end-to-end. Contact us with the molecule, the destination authority and the clinical justification — we'll come back within one working day.